This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01299285
First received: February 16, 2011
Last updated: May 15, 2017
Last verified: May 2017
  Purpose
This is a single dose study of radiolabeled [14C]-LY3009104 in healthy male volunteers to study the absorption, distribution, metabolism, and elimination of LY3009104. This study requires minimum of 7 days and maximum of 22 days stay. This study is for research purposes only and is not intended to treat any medical condition.

Condition Intervention Phase
Healthy Volunteers Drug: LY3009104 Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Other
Official Title: Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Male Subjects

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Percentage of the Total Radioactive Dose Administered Excreted From Urine and Feces [ Time Frame: Baseline up to 120 hours ]

Secondary Outcome Measures:
  • Plasma Pharmacokinetics: LY3009104 Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)] [ Time Frame: Baseline up to 48 hours ]
  • Plasma Pharmacokinetics: Radioactivity Area Under the Concentration-Time Curve From Time Zero to Infinity [AUC(0-∞)] [ Time Frame: Baseline up to 48 hours ]
  • Plasma Pharmacokinetics: Maximum Observed LY3009104 Concentration (Cmax) [ Time Frame: Baseline up to 48 hours ]
  • Plasma Pharmacokinetics: Maximum Observed Radioactivity Concentration (Cmax) [ Time Frame: Baseline up to 48 hours ]
  • Plasma Pharmacokinetics: LY3009104 and Radioactivity Time to Maximum Observed Concentration (Tmax) [ Time Frame: Baseline up to 48 hours ]
  • Percentage of Dose of LY3009104 and LY3009104 Metabolites in Urine [ Time Frame: Baseline up to 48 hours ]
    Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the urine are reported. Only those metabolites that were detectable in the urine are included in the report.

  • Percentage of Dose of LY3009104 and LY3009104 Metabolites in Feces [ Time Frame: Baseline up to 72 hours ]
    Percentages of LY3009104 (parent) and LY3009104 metabolites that were excreted in the feces are reported. Only those metabolites that were detectable in the feces are included in the report.

  • Percentage of Total Radioactivity of LY3009104 and LY3009104 Metabolites in Plasma [ Time Frame: Baseline up to 24 hours ]

Enrollment: 6
Study Start Date: February 2011
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LY3009104
Single 10-milligram (mg) oral dose containing 100 microcuries of 14C-labeled LY3009104
Drug: LY3009104
Administered orally
Other Name: Baricitinib

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Overtly healthy males, as determined by medical history and physical examination
  • Will either be sterile or, if sexually active, agree to use a reliable method of birth control from check-in until 3 months after the end of the study
  • Body mass index (BMI) between 19 and 30 kilogram/square meter (kg/m²)
  • Experience on average 1 to 2 bowel movements per day
  • Clinical laboratory test results within the normal reference range for the clinical research unit (CRU) or, results with acceptable deviations which are judged to be not clinically significant by the investigator
  • Normal blood pressure and heart rate (sitting) as determined by the investigator
  • Venous access sufficient to allow blood sampling
  • Are reliable and willing to make themselves available for the duration of the study, and are willing to abide by the CRU policies and procedures, and study restrictions
  • Have given written informed consent approved by Lilly and the Institutional Review Board (IRB) governing the CRU

Exclusion Criteria:

  • Are currently enrolled in, have completed or discontinued, a clinical trial involving an investigational product or are concurrently enrolled in any other type of medical research judged not to be scientifically, or medically compatible with this study
  • Have known allergies to LY3009104, related compounds, or any components of the formulation
  • Have previously received the investigational product in this study, have completed or withdrawn from this study or any other study investigating LY3009104
  • History or presence of an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, is clinically significant
  • Current or recent history (<30 days prior to Screening and/or <45 days prior to Check-in) of a clinically significant bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
  • An Absolute Neutrophil Count (ANC) less than 2000 cells/microliter. For abnormal values a single repeat will be allowed
  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Show evidence of significant active neuropsychiatric disease and in particular evidence of significant medical or psychiatric illness within the past 12 months
  • Have known substance dependence or abuse within 6 months prior to the study (according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition [DSM-IV] diagnosis), or regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
  • Show evidence of hepatitis C and/or positive hepatitis C antibody
  • Evidence hepatitis B (active or surface antigen positive [HBsAg+]) or hepatitis B core antibody positive, hepatitis B surface antibody negative (HBcAb+, HBsAb-)
  • Use of prescription medication; over-the-counter medication; or herbal preparations containing St. John's Wort, kava, garlic, ginger, gingko biloba, or guarana within 14 days prior to admission
  • Consumption of grapefruit or grapefruit-containing foods or juices within 7 days prior to dosing or at any time during the study
  • Have an average weekly alcohol intake that exceeds 15 units per week, or are unwilling to stop alcohol consumption for the duration of the study (1 unit = 12 oz or 360 milliliter (mL) of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
  • Consume 5 or more cups of coffee (or other beverages of comparable caffeine content) per day, on a habitual basis, or any subjects unwilling to adhere to study caffeine restrictions (no caffeine 48 hours prior to admission until the end of study
  • Use of tobacco or nicotine-replacement products within the 6 months prior to study entry or at any time during the study
  • Have donated blood of more than 500 mL within the last month
  • Have participated in a 14C-study within the last 6 months prior to Check-in for this study. The total exposure from this study and the previous study must be within the Code of Federal Regulations (CFR) recommended levels considered safe (per 21 CFR 361.1), for example less than 5,000 millirem (mrem)/year whole body annual exposure
  • Exposure to significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01299285

Locations
United States, Wisconsin
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559), Mon - Fri, 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Madison, Wisconsin, United States
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559, Mon - Fri, 9AM - 5PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01299285     History of Changes
Other Study ID Numbers: 14010
I4V-MC-JADG ( Other Identifier: Eli Lilly and Company )
Study First Received: February 16, 2011
Results First Received: March 10, 2017
Last Updated: May 15, 2017

Keywords provided by Eli Lilly and Company:
Absorption
Distribution
Metabolism
Excretion
Mass balance
Metabolic profile
Radiolabeled study
14C

ClinicalTrials.gov processed this record on June 26, 2017